You searched for "Barcelona"

76 results found

Do not hesitate and start using the hashtag, #UroSoMe!

In recent years, the digitisation of scientific information has been astonishing and the use of social networks has been increasing worldwide. Social networks play a fundamental role in the dissemination of information and scientific knowledge in the field of urology...

Read all about it Mar/Apr 2020

Read all about it... It can be awkward when a patient asks you about a report in their favourite tabloid detailing an amazing research breakthrough or a ‘cutting-edge’ new treatment / test and you don’t know what they are talking...

Read all about it May/Jun 2019

It can be awkward when a patient asks you about a report in their favourite tabloid detailing an amazing research breakthrough or a ‘cutting-edge’ new treatment / test and you don’t know what they are talking about! So this section...

Sepsis syndrome in urology

There are approximately 100,000 cases of sepsis per year in the UK, of which 37,000 result in death (this is more than prostate cancer, breast cancer, HIV / AIDS and road traffic accidents combined). Urosepsis is defined as sepsis caused...

Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for SCC

Squamous cell carcinoma (SCC) of the bladder is more commonly seen in Egypt due to schistosomiasis (bilharziasis) and accounts for 2% to 5% of all bladder tumours. Schistosomiasis is found in the bladder vasculature and leads to chronic inflammation causing...

Renal fossa recurrence after nephrectomy for renal cell carcinoma

This paper is an analysis of 36 years of radical nephrectomy for renal cell carcinoma in the Mayo Clinic (1970-2006). In particular, it contains an analysis of the risk of renal fossa recurrence after nephrectomy (partial nephrectomies are not included)...

Secondary bladder cancer following upper tract urothelial cancer

Upper tract urothelial carcinoma (UTUC) comprises <5% of all urothelial cancers. A certain proportion of patients with UTUC will develop secondary bladder urothelial cancer (BUC). This paper has retrospectively examined records obtained from several cancer USA population-based registries of more...

Understanding Stauffer’s syndrome

Who was Stauffer and what is Stauffer’s syndrome? Maurice Stauffer (1915-1994) was a gastroenterologist at the Mayo Clinic in Rochester, United States, and in 1961 first characterised the non-metastatic, paraneoplastic effects of renal cell carcinoma (RCC) on liver size and...

Sarcomatoid renal cell carcinoma

Renal cell carcinoma (RCC) represents 2-3% of all cancers [1]. It is an adenocarcinoma making up 85% of all renal malignancies. Sarcomatoid transformation is a microscopically identified feature of RCC accounting for 5% of all RCCs [2]. Known as sarcomatoid...

Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high-risk UTUC

High-risk upper tract urothelial carcinoma (UTUC) has been associated with poor survival outcomes. The authors evaluated the role of neoadjuvant chemotherapy in high-risk cases prior to radical nephroureterectomy (RNU) in terms of pathological stage of the final surgical specimen. A...

Non-urothelial tumours of bladder – impact on oncological outcomes

Non-urothelial bladder tumours are not very common and they are generally considered to be high risk tumours when compared to standard urothelial tumours. In this study the researchers analysed the oncological outcomes of patients with such histology in comparison to...

Curing pure CIS with radical surgery: lessons learned

As carcinoma in situ (CIS) theoretically has no ability to invade or metastasise, performing radical cystectomy for CIS-only disease should be curative. In this single centre review over 37 years, 1964 patients undergoing cystectomy were analysed with 52 undergoing surgery...